Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876590 | 0.89 | P2RX7 (0.79) | P2RX7P2RY12 | |
| SCHEMBL21753443 | 0.88 | P2RX7 (1.00) | P2RX7P2RY12 | |
| SCHEMBL6572116 | 0.86 | P2RX7 (0.76) | P2RX7 | |
| SCHEMBL4883532 | 0.86 | P2RX7 (0.74) | P2RX7P2RY12 | |
| SCHEMBL6571527 | 0.85 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL6574267 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL7568669 | 0.85 | P2RX7 (0.73) | P2RX7 | |
| SCHEMBL21753384 | 0.85 | P2RX7 (1.00) | P2RX7P2RY12 | |
| SCHEMBL7568675 | 0.84 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL7571588 | 0.84 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141034-A1 | ADAMANTANE-1-CARBONYL THIOUREA, AS P2X RECEPTOR ANTAGONIST | COMSATS University Islamabad (PK) | 2023-05-11 | — | — | US | disclosed |
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2021-10-21 | — | — | US | disclosed |
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2021-10-21 | — | — | US | disclosed |
| WO-2020037350-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020037350-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2020-02-27 | — | — | WO | disclosed |
| WO-2008064432-A1 | POLYCYCLIC MOLECULAR COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141034-A1 | ADAMANTANE-1-CARBONYL THIOUREA, AS P2X RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885P2RY12 22/4885 |
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | P2RX1, P2RX3, P2RX5 | P2RX7 4/4885P2RY12 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.